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Purpose: To explore the ocular manifestations of cobalamin C (cblC) deﬁciency, an inborn error of intra-
cellular vitamin B12 metabolism.
Design: Retrospective, observational case series.
Participants: Twenty-ﬁve cblC patients underwent clinical and ophthalmic examination at the National In-
stitutes of Health between August 2004 and September 2012. Patient ages ranged from 2 to 27 years at last
ophthalmic visit, and follow-up ranged from 0 to 83 months (median, 37 months; range, 13e83 months) over a
total of 69 visits.
Methods: Best-corrected visual acuity, slit-lamp biomicroscopy, dilated fundus examination, wide-ﬁeld
photography, fundus autoﬂuorescence imaging, sedated electroretinography, optical coherence tomography,
genetics and metabolite assessment.
Main Outcome Measures: Visual acuity and presence and degree of retinal degeneration and optic nerve
pallor.
Results: Nystagmus (64%), strabismus (52%), macular degeneration (72%), optic nerve pallor (68%), and
vascular changes (64%) were present. c.271dupA (p.R91KfsX14) homozygous patients (n ¼ 14) showed early and
extensive macular degeneration. Electroretinography showed that scotopic and photopic responses were
reduced and delayed, but were preserved remarkably in some patients despite severe degeneration. Optical
coherence tomography images through the central macular lesion of a patient with severe retinal degeneration
showed extreme thinning, some preservation of retinal lamination, and nearly complete loss of the outer nuclear
layer. Despite hyperhomocysteinemia, no patients exhibited lens dislocation.
Conclusions: This longitudinal study reports ocular outcomes in the largest group of patients with cblC
deﬁciency systematically examined at a single center over an extended period. Differences in progression and
severity of macular degeneration, optic nerve pallor, and vascular attenuation between homozygous c.271dupA
(p.R91KfsX14) patients and compound heterozygotes were noted. The pace and chronicity of ophthalmic
manifestations lacked strict correlation to metabolic status as measured during visits. Prenatal or early treatment,
or both, may have mitigated ocular disease, leading to better functional acuity, but patients still progressed to
severe macular degeneration. The effects of prenatal or early treatment, or both, in siblings; the manifestation of
severe disease in infancy; the presence of comorbid developmental abnormalities; and the possible laminar
structural defect noted in many patients are ﬁndings showing that cblC deﬁciency displays a developmental as
well as a degenerative ocular phenotype. Ophthalmology 2016;123:571-582 ª 2016 Published by Elsevier on
behalf of the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Cobalamin C (cblC) deﬁciency (Online Medelian Inheri-
tance in Man no., 277400),1,2 an inborn error of intracellular
vitamin B12 metabolism, is caused by mutations in the
MMACHC gene3 (Online Medelian Inheritance in Man no.,
*609831) that leads to impaired intracellular synthesis of 50-
adenosyl- and methylcobalamin, cofactors for the enzymes
methylmalonyl-CoA mutase and methionine synthase,
respectively. As a result, patients display combined meth-
ylmalonic acidemia and hyperhomocysteinemia. Because
the enzymatic defect affects the remethylation of homo-
cysteine, hypomethioninemia and a generalized impairment
in methyl transfer reactions also are present. 2016 Published by Elsevier on behalf of the American Academy of Ophthalmology.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).The prevalence of cblC deﬁciency, as estimated in 2010 by
newborn screening studies, is approximately 1 in 100 000 in a
United States population,4 but can vary widely by ethnicity.
For instance, cblC deﬁciency is reported in as many as 1 in
37 000 persons in a particular Hispanic population in
California.5 Historically, patients with cblC deﬁciency have
been categorized based on age at onset, with the early-onset
type manifesting symptoms before 4 years of age and the
late-onset type manifesting symptoms after 4 years of age.6
However, the disorder can present at any point from the
prenatal period to adulthood. Prenatal- and infantile-onset
patients show the most severe and progressive metabolic,571http://dx.doi.org/10.1016/j.ophtha.2015.10.041
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Ophthalmology Volume 123, Number 3, March 2016neurologic, and ophthalmic manifestations. They can
demonstrate intrauterine growth restriction; chronic failure to
thrive; hemolytic uremic syndrome; developmental delay,
regression, or both; microcephaly; nystagmus; pigmentary
retinopathy; and neurologic dysfunction.2,6 Patients with
noninfantile onset more typically demonstrate developmental
delay or regression, or both, characterized by declines in
school or work performance, thromboembolic events, pro-
gressive encephalopathy, psychiatric symptoms, leukoence-
phalopathy, or subacute combined degeneration of the spinal
cord.2,6
The phenotype of cblC deﬁciency seems to correlate with
genotype, particularly with regard to the age at onset and
disease severity. There are more than 50 known mutations
withinMMACHC among patients, but the most common is a
frameshift mutation c.271dupA (p.R91KfsX14) that ac-
counts for approximately 40% of alleles3 and is associated
with early-onset disease, typically in the ﬁrst year of life.3,7,8
Cobalamin C deﬁciency is one of the few disorders
associated with infantile maculopathy, which has been
documented as early as 3.5 months of age.9 Wandering eye
movements, inability to ﬁxate, and nystagmus often are the
ﬁrst clinical signs of eye disease in infants with cblC
deﬁciency.10,11 Maculopathy and progressive retinal
dysfunction11,12 are seen in most patients with early-onset
cblC deﬁciency and rarely in those with late-onset cblC
deﬁciency.12,13 The ﬁrst funduscopic signs can include
pigmented macular changes that progress to a bull’s-eye
maculopathy. This maculopathy is characterized by a
hypopigmented perimacular zone surrounded by a hyper-
pigmented ring, typically progresses to the periphery of the
retina,9,10 and is accompanied by measurable dysfunction on
electroretinography (ERG) testing.11,14 Optic nerve atrophy
also is noted frequently.10,15,16
A recent questionnaire-based survey reported a series of
88 European patients with some ocular ﬁndings included.17
However, as noted in a recent comprehensive review of
cblC deﬁciency,18 publications that detail ophthalmic
parameters are sparse. To date, there are fewer than 100
patients described for whom detailed ocular examination
results are included (only 61 of these patients are
identiﬁed by genotype), with the largest studies reporting
results from 12 patients.14,19 Because most patients were
examined at different facilities, ophthalmologic data varied
between reports, genotypes often were not recorded, and
complete metabolic parameters were not measured. Hence,
there is a need for a detailed, single-center study that takes
into account genotype, metabolic parameters, and ocular
phenotypes to advance the understanding of cblC-related
ophthalmologic manifestations.
This longitudinal study examined the ophthalmic
phenotype of cblC deﬁciency as ascertained in a large group
of patients examined systematically at a single center in the
setting of a dedicated natural history study. The cohort
included 25 patients ranging in age from 2 to 27 years who
were studied serially over a 10-year period. We character-
ized the natural history of the progression and severity of
macular degeneration, optic nerve pallor, and vascular
attenuation in the patients. Autoﬂuorescence photography,
ocular coherence tomography, and ERG also were used to572further our understanding of the structural and functional
origins of the ocular manifestations.
We found that the pace and chronicity of the ophthalmic
manifestations lacked a strict correlation to metabolic status
as measured during protocol visits. The presence of severe
disease in infancy, indications of a developmental abnor-
mality in the retinal structure of patients, and the occurrence
of comorbid developmental defects (e.g., microcephaly,
cardiac defects, or left ventricular noncompaction) suggest
that cblC deﬁciency can feature developmental as well as
degenerative phenotypes. Our data present an important set
of ocular outcome parameters that will be useful for the
community to help examine new therapies for the loss of
vision in these patients.
Methods
The patients were evaluated under protocol 04-HG-0127, “Clinical
and Basic Investigations of Methylmalonic Acidemia and Related
Disorders” (clinicaltrials.gov identiﬁer, NCT00078078). The
research adhered to the tenets of the Declaration of Helsinki and
was approved by the National Human Genome Research Institute
Institutional Review Board. Informed consent from patients,
guardians, or both (including consent for use of patient photo-
graphs) was obtained.
All patients with a diagnosis of cblC deﬁciency, determined by
cellular enzymologic results, mutation analysis of the MMACHC
gene, or both who underwent an ophthalmic examination between
August 2004 and September 2012 at the National Institutes of
Health Clinical Center were included in this report after data re-
view and abstraction. All ophthalmic examinations were carried
out by one or more of the authors (B.P.B., W.M.Z.).
The complete ophthalmic examinations included visual acuity
(VA) and ﬁxation: Snellen visual VA and best-corrected Snellen VA
(BCVA); ﬁx and follow (FF); or central, steady, and maintained. In
the youngest patients with quantiﬁable acuity, those younger than 6
years, Teller acuity cards (n ¼ 3) or HOTV (n ¼ 4) were used in
acuity assessments. In those patients 6 years of age and older at the
time of examination, either Early Treatment Diabetic Retinopathy
Study charts (n ¼ 14), Early Treatment Diabetic Retinopathy Study
short charts (n¼ 10), HOTV charts (n¼ 7), or picture charts (n¼ 4)
were used, with 1 patient older than 20 years (patient 18) assessed
using a Teller acuity chart (because of inability to cooperate with
other methods). When possible, the evaluation also included slit-
lamp biomicroscopy, dilated fundus examination with an indirect
ophthalmoscope, wide-ﬁeld photography (Optos ultrawide-ﬁeld
retinal imaging device; Dunfermline, Scotland), fundus auto-
ﬂuorescence imaging, and sedated ERG with an Espion consol
(Diagnosys LLC, Lowell, MA) conducted according to the Inter-
national Society for Clinical Electrophysiology of Vision Stan-
dards.20 Cirrus HD-OCT (Carl Zeiss Meditec, Inc., Dublin, CA)
spectral-domain optical coherence tomography (OCT) scans were
obtained by certiﬁed technicians. The scans were assessed for
quality and were examined for loss of the inner segmenteouter
segment photoreceptor junction in the macular area and at the edge
of the macular lesion.
Treatment regimens varied widely between the different meta-
bolic centers that referred patients to our study. All patients received
intramuscular hydroxocobalamin (1e25 mg/day, 1e7 times/week),
and variably, betaine (30e300 mg/kg daily), carnitine (10e70 mg/
kg daily), and folic or folinic acid (1 or 5e10mg daily), respectively.
Whole-protein consumption ranged from 0.7 to 2.5 g/kg daily.
Aspirin also was administered to some patients.1,2,21 In utero treat-
ment for the 2 younger affected siblings was as follows. For patient
Brooks et al  Manifestations of Cobalamin C Deﬁciency4, the mother received 1 mg hydroxocobalamin per week intra-
muscularly starting at 20 weeks’ gestation after amniocentesis
conﬁrming the diagnosis of cblC deﬁciency. Treatment was
increased to 3 mg thrice weekly until delivery. Patient 4 was treated
with hydroxocobalamin injections immediately after birth. For
patient 5, the mother received 1 mg oral cyanocobalamin daily
throughout the pregnancy. Patient 5 received the diagnosis of cblC
at 4 days of age and was treated with hydroxocobalamin injections
(1 mg/day intramuscularly) starting at 5 days.Results
A total of 25 patients with cblC deﬁciency underwent examination
by a National Eye Institute ophthalmologist (B.P.B. or W.M.Z.)
experienced with this disorder as part of the study (Table 1). The
patients ranged in age from 2 to 27 years at the most recent
ophthalmic visit. Ten patients were female and 15 were male.
Twenty patients with infantile onset plus 1 patient with delayed
onset were classiﬁed as infantile onset, plus 4 patients with late
onset, for a total of 25 patients. (Table 1). Two more infantile-
onset patients were younger siblings of already diagnosed in-
dividuals and were monitored during the mothers’ pregnancy.
Patient 7 had a delayed diagnosis at 2 years of age but is still
classiﬁed as having infantile onset because of genotype and med-
ical records from other institutions. The remaining 4 patients in the
study were classiﬁed as having noninfantile onset and were diag-
nosed at 3 years of age or older (patients 22-25). No formal age of
diagnosis was recorded for patient 24, however, she ﬁrst experi-
enced mental decline at age 13 and joined this study at age 20. The
patient genotypes are listed in Table 1. Fourteen patients, all with
infantile onset, had developmental abnormalities including left
ventricular noncompaction cardiomyopathy,22 fetal hydrops,
intrauterine growth restriction or small size for gestational age,
Ebstein’s anomaly, microcephaly, or prenatal microcephaly
(Table 1). The developmental abnormalities in patient 3 have
been reported previously.22
Thirteen of the patients were seen at least twice, with a median
ophthalmic follow-up time of 37 months (range, 13e83 months;
Table 1), for a collective total of 69 visits. Among the patients
were 2 sets of brothers; in one case, the mother, while pregnant
with the younger sibling, was treated with intramuscular
hydroxycobalamin. Fourteen patients (56%) were homozygous
for the c.271dupA (p.R91KfsX14) mutation, with the remainder
of the patients distributed across 9 other genotypes.
The metabolites of the patients at the time of the last ophthalmic
visit are reported in Table 1. Median serum methylmalonic acid
(MMA) was 5.5 mM (range, 0.1e31 mM; normal, <0.4 mM),
median plasma total homocysteine (tHcy) was 53 mm (range,
4e91.7 mM; normal, 0e13 mM), and median plasma methionine
was 23 mM (range, 9e55 mM; normal, 7e47 mM). Only patients
24 and 25, both with noneinfantile-onset cblC deﬁciency, had
normal levels of all 3 metabolites at the time of the last
ophthalmic visit (Table 1).
Brain magnetic resonance imaging scans from 13 of 25 patients
were available for review. Only 1 individual had a diagnosis of
hydrocephalus and had a ventriculo-peritoneal shunt placed at 1 year
of age (patient 10). Five patients had evidence of white matter dis-
ease (leukoencephalopathy; Table 1). The detailed neuroradiologic
ﬁndings in this cohort will be the subject of a future report.
Ocular Characteristics
Twenty-three of the 25 patients (92%) showed a degree of ocular
abnormality that exceeded the simple need for corrective lenses
(Table 1). Seven patients, despite being of ages normally able tocooperate with VA testing, were neurologically impaired and
unable to cooperate with VA testing. One patient was simply
able to FF (patient 8), 2 patients were unable to FF (patient 1, 2
years of age, and patient 7, 12 years of age), and 4 patients
between 2 and 12 years of age (patients 17 and 19e21)
exhibited central, unsteady maintained vision.
Manifest nystagmus was seen in 16 patients (64%) and stra-
bismus was seen in 13 patients (52%; Table 1). Although in
general anterior segment examinations were unremarkable, in a
27-year-old patient (patient 14), guttae were present in the
corneal endothelium of both eyes. Examinations showed a wide
range of VAs. The 18 patients who had quantiﬁable VA had vision
ranging from 0.1 to 2.3 logarithm of the minimum angle of res-
olution (logMAR), with a median acuity of 0.95 (Snellen equiv-
alent, 20/180; Table 1). Lowered BCVA, when quantiﬁable,
ranged from 0.9 to 1.5 logMAR, with a median of 1.3 logMAR
(Snellen equivalent, 20/400; Table 1). Because of limitations in
patient cooperation, patients were not always assessed for both
VA and BCVA. Reduced BCVA was either quantiﬁed or
reported in the medical record without quantiﬁcation in 17
patients (68%). Eighty-four percent of patients required correc-
tive lenses.
The box plot in Figure 1 shows all measurable and
nonquantiﬁable (central, steady, and maintained or FF) VAs in
the patient population over a range of ages. Depending on the
duration of follow-up, an individual patient can appear in more
than 1 age category. Patient age at onset and genotype are indicated
by the shape and shading of the symbols. The group as a whole had
substantial visual impairment at ages older than 5 to 10 years, with
a median VA of 0.9 logMAR, and a number of patients were at or
past the 1.0-logMAR (Snellen equivalent, 20/200) legally blind
threshold. The median for the age group older than 10 to 15 years
was 1.4 logMAR, and VA continued to worsen in the older age
groups, with a median value of 1.6 logMAR in the group older than
20 years of age. All of the infantile-onset patients older than 15
years were over the legally blind threshold. Although c.271dupA
(p.R91KfsX14) homozygous patients universally were affected
severely, c.271dupA (p.R91KfsX14) heterozygous and the other
genotype infantile-onset patients also experienced some reduced
VA. A number of patients with both c.271dupA (p.R91KfsX14)
and other genotypes were affected severely, both neurologically
and ophthalmologically, and were able only to FF, 1 patient
intermittently (Table 1; Fig 1).
Although central nervous system damage resulting from the
underlying metabolic disease also can limit vision (Table 1), a
prominent ophthalmologic feature in 72% of patients is some
form of retinal degeneration. This degeneration, shown in
Figure 1, is variable in pacing and degree. The most severe
patients demonstrate macular atrophy in infancy, as did 7
patients (Table 1). An example of early severe manifestation of
cblC deﬁciency is the macular coloboma in a 12-month-old pa-
tient (patient 3; Fig 2A). The macular coloboma was documented
as being present at 6 months of age or earlier. More typically,
macular atrophy is observed beginning in the ﬁrst decade of life.
This may take on a bull’s-eye appearance (n ¼ 4 with history of
bull’s-eye in 3 additional patients; Table 1; Fig 2B) or a more
generalized maculopathy (Fig 2D). Progression continues to
involve the remaining macula and periphery (Fig 2B, C, E, F),
resulting in end-stage retinal degeneration (which also can take
the form of coloboma-like lesions) and legal blindness. Figure 2D
shows end-stage degeneration in a 9-year-old patient. This end
stage may occur as early as the ﬁrst decade (patients 3 and 6),
although progression to this point more typically takes place early
in the second decade of life or later (Fig 1). The macular status of
each patient at the time of study entry (as determined either by
masked fundus photographs read by an experienced reader or573
Table 1. Metabolic and Ophthalmic Characteristics of Cobalamin C Deﬁciency Patients at Most Recent Ophthalmic Visit
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1 F none nr 2 2 5 48 3.3 55 1 n/a + - NoFF + >1 y - - n/r -
2 M SGA nr 3 3 <1NS 34 3.6 40 1 n/a - - 0.9* + 3 y - - + +D
3 F
LVNC, fetal hydrops, 
coloboma
- 6 1 <1 53 5.7 22 7 37 + + 2.3* + >1 +END - + 3 +D 14 
4 1 M IUGR nr 10 4 pre 44 2.2 28 7 39 - + 1 + 4+M +P + - 2 +T
5 2 M none nr 10 5 pre 70 25 23 5 63 - - 0.8* + 5+M +P + - 1 +T
6 2 M none + 11 6 1 78 31 31 5 63 + + 1.3 + 6+P +END + - 1 +D
7 M none nr 12 9 26 65.5 1.4 16 2 28 + + NoFF n/a 11 y - - + +
8 1 M SGA nr 13 6 2 65 0.5 19 8 83 - + FF n/a 6+P +P - - 2 +T
9 M none - 15 13 <1 56 3 27 3 13 - - 0.9 + 13+END +END hx13 - 3 +D
10 F LVNC*, hydrocephalus - 18 12 2 86 15 18 4 62 + - 1.3 + 12+END +END - - 3 +D
11 M LVNC - 18 12 3 65 19 28 3 36 + + 1.5 + >1 +END - + 3 +D 15
12 M IUGR/SGA - 19 19 4 53 1.3 24 1 n/a + - 1.4 + 19 y - - + +
13 M LVNC nr 26 22 4 64 22 18 5 50 + + 1.6* + >1 +P - - 2 +D
14 F Ebsteins anomaly, LVNC + 27 26 3 91.7 19 12 2 27 + + 1.5 + >1 +END - + 2 +D 16
15 F congenital microcephaly nr 4 4 1NS 24 0.9 8 1 + + 0.6* + n - - n/r +
16 M prenatal microcephaly nr 10 10 3 82 20 19.5 1 n/a
n/a
+ + 0.4* + n - - - -
c.271dupA 
p.R91KfsX14 
(ex2/dup, frameshift) 
 c.457C>T p.R153X 
(ex4/nonsense)
17 F prenatal microcephaly + 12 9 5 68 4.3 29 4 31 + + CUSM + 9+M +M + - 1 +T
c.271dupA 
p.R91KfsX14 
(ex2/dup, frameshift) 
c.600G>A p.W200X 
(ex4/nonsense)
18 M microcephaly nr 22 17 6 94 5.9 20 1 n/a + + 1.2* + n - - - -
c.3G>A p.M1?           
(ex1/start codon)
c.3G>A p.M1? 
(ex1/start codon)
19 F none + 4 4 2 44 3.7 21 1 n/a + + CUSM n/a 3 y - - + +
c.440G>A p.G147D 
(ex4/missense)
 c.619dupG 
p.D207GfsX38 
(ex4/dup, frameshift)
20 M none nr 2 2 <1NS 28 8.7 37 1 n/a + - CUSM n/a >1 y hx - n/r -
c.471G>A p.W157X 
(ex4/nonsense)
c.666C>A p.Y222X 
(ex4/nonsense)
21 M LVNC* nr 4 5 <1NS 45 7.5 53 1 n/a + - CUSM n/a >1 y  hx - + +
c.271dupA 
p.R91KfsX14 
(ex2/dup, frameshift) 
 c.482G>A p.R161Q 
(ex4/missense)
22 F none - 8 8 4011 19 6.8 20 1 n/a - - 0.1 - n - - - -
23 M none + 7 7 6411 30 5.5 17 1 n/a - - 0 - n12 - - - -
24 F none - 21 21 nr 8 0.5 41 1 n/a - - 0 - n - - - - 17
c.440G>C p.G147A 
(ex4/missense)
c.440G>C p.G147A 
(ex4/missense)
25 F none - 9 8 91 4 0.1 31 2 13 - - 0.6* + n - - - - 18
Number 25 10, 15 14 5 69 545 16 13 17 18 4 3 16 17
Median 10 8 3 53 5.5 23 2 37 0.95 1.319
Avg 12 9 10 52.8 8.64 26.3 2.8 42 0.97 1.319
% of total 64% 52% 68% 72% 16% 12% 64% 68%
Genotype (exon/type of mutation)
c.394C>T p.R132X 
(ex3/nonsense)
c.394C>T p.R132X  
(ex3/nonsense)
c.271dupA 
p.R91KfsX14   
(ex2/duplication, 
frameshift) 
c.271dupA 
p.R91KfsX14 
(ex2/duplication, 
frameshift) 
c.271dupA 
p.R91KfsX14 
(ex2/dup, frameshift) 
c.331C>T p.R111X 
(ex3/nonsense)
Patient totals
avg ¼ average; CUSM ¼ central, unsteady, and maintained; Dx ¼ diagnosis; F ¼ female; FF ¼ ﬁx and follow; Hcy ¼ homocysteine; hx ¼ history; IUGR ¼
intrauterine growth restriction; logMAR ¼ logarithm of the minimum angle of resolution; LVNC ¼ left ventricular noncompaction cardiomyopathy;
LVNC* ¼ prominent trabeculations of the left ventricle suggestive of left ventricular noncompaction; M ¼ male; MMA ¼ methylmalonic acid; n ¼ No;
n/a ¼ not applicable; NoFF ¼ no ﬁx and follow; n/r ¼ not reported; OD ¼ left eye; SGA ¼ small for gestational age; VA ¼ visual acuity; y ¼ Yes.
Shading indicates values outside of normal range.
*Uncorrected visual acuity.
1, 2 ¼ Sibling pairs.
3 ¼ Plasma homocysteine (normal, 0e13 mM).
4 ¼ Serum methylmalonic acid (normal, 0.4 mM).
5 ¼ Plasma methionine (normal, 7e47 mM).
6 ¼ Right eye visual acuity reported because there were not large differences between right-eye and left-eye values.
7 ¼ As determined by a masked reading of available patient photographs.
8 ¼ Macular atrophy key: N ¼ none; M ¼ macular; P ¼ peripheral; END ¼ end stage.
9 ¼ Vascular changes key: þ1 ¼ mild; þ2 ¼ moderate; þ3 ¼ severe.
10 ¼ Degree of pallor key: T ¼ temporal; D ¼ diffuse.
11 ¼ Some signs or symptoms in infant period, but diagnosis delayed.
12 ¼ Possible subclinical macular degeneration not ruled out.
13 ¼ Irregular macula at 18 days of age, a “grey” macula at 3 months of age, and a mild bull’s eye at 1 year of age.
14 ¼ Coloboma ﬁrst reported at 3 months of age.
15 ¼ Abnormal electroretingraphy results with rod and cone abnormalities at 1 month and 22 months of age.
16 ¼ Guttae-like formations noted.
17 ¼ Drusen-like deposits noted.
18 ¼ Patchy vision not resulting from macular atrophy, occult maculopathy, or occult optic neuropathy.
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Figure 1. Box-and-whisker plots showing all recorded acuities at all visits. Visual acuity (VA) of many patients with cobalamin C deﬁciency deteriorates to
legal blindness, often in the ﬁrst decade of life. Because of limitations in patient cooperation, patients were assessed for either VA or best-corrected VA
(BCVA), and those values are reported. The right-eye VA and BCVA are reported because left-eye values were consistent within patients. *Outlier.
CUSM ¼ central, unsteady, and maintained; DupA homozyg ¼ homozygotes; DupA heterzyg ¼ heterozygotes; FF ¼ ﬁx and follow only; logMAR ¼
logarithm of the minimum angle of resolution; Non-DupA ¼ c.271dupA.
Brooks et al  Manifestations of Cobalamin C Deﬁciencyaccording to their medical records from before study entry) and
then also at the most recent ophthalmic visit are included in
Table 1.
An important corollary to these observations involves prenatal
diagnosis, which facilitated treatment either prenatally or soon after
birth. In the cases pictured in Figure 2BeG, mothers with a ﬁrst
child diagnosed with cblC deﬁciency had affected fetuses. The
prenatal diagnosis allowed the affected newborns to be treated
with intramuscular hydroxocobalamin immediately after birth
(patient 4) or within a few days of birth (patient 5). Additionally,
the mother of patient 4 was treated with intramuscular
hydroxocobalamin as soon as the prenatal diagnosis was
conﬁrmed (see “Methods”). Empiric treatment with contemporary
vitamin and dietary therapy resulted in children with less
cognitive dysfunction (data not shown), better visual function,
and less severe retinal ﬁndings (Table 1; Figure 2C vs. 2D and
Fig 2F vs. 2G). The progression of retinopathy was delayed
compared with that of the older sibling; however, it still
progressed (Fig 2B, C vs. 2D and Fig 2E, F vs. 2G) and
functional acuity still was affected severely. These data suggest
that hydroxocobalamin therapy can mitigate, but does not
prevent, symptoms or eventual progression of the retinal disease.
A potential confounder to this conclusion is that early treatment
also may help to prevent other morbidities such as metabolic
decompensation or other organ involvement.
Similar to those identiﬁed early because of affected older sib-
lings, several patients in this cohort were diagnosed through
newborn screening (Table 1; patients 2, 15, 20, and 21) and
received empiric contemporary vitamin and dietary treatment.
Our examinations showed that all of the newborn screen-positive
patients demonstrated symptoms at the ﬁrst study ophthalmic ex-
amination with either clinically apparent macular degeneration (in
3 patients) or lowered BCVA (1 patient; Table 1). Therefore, thetreatment did not seem to prevent the ocular manifestations of
cblC deﬁciency.
Although c.271dupA (p.R91KfsX14) homozygous patients
such as those pictured in Figure 2 show the most extensive retinal
degeneration, some degree of degeneration was exhibited by 4 of
the other 9 genotypes of patients in the study. These genotypes
were c.271dupA (p.R91KfsX14), c.457C>T (p.R153X); c.3G>A
(p.M1?); c.3G>A (p.M1L), c.440G>A (p.G147D), c.619dupG
(p.D207GfsX38); and c.471G>A (p.W157X), c.666C>A
(p.Y222X). All were patients with infantile-onset disease (Table 1).
The comparison of patients with similar plasma metabolite
levels but differing genotypes showed that the genotype rather than
metabolite levels were more predictive. Only 2 patients in the study
had higher than the normal upper limit of methionine at the last
ophthalmic examination, a 2-year old patient (patient 1) homozy-
gous for c.271dupA (p.R91KfsX14) and a 4-year old (patient 21)
with c.471G>A (p.W157X), c.666C>A (p.Y222X) genotypes.
Both patients had some degree of macular degeneration (Table 1).
Photographs were not available because of limited cooperation by
the patients. However, 3 patients with similarly high plasma tHcy
and MMA concentrations are shown in Figure 3AeC. The
c.271dupA (p.R91KfsX14) homozygous patients (patient 14 [Fig
3A] and patient 11 [Fig 3B]) showed end-stage macular degener-
ation; however, the patient with c.271dupA (p.R91KfsX14),
c.600G>A (p.W200X) (patient 18; Fig 3C) had relatively normal
fundus ﬁndings despite comparable metabolite proﬁles as those
severely affected. Similarly, patients 15 and 16, with infantile-
onset disease and genotype c.271dupA (p.R91KfsX14),
c.331C>(p.R111X), had widely variable metabolite levels and no
macular atrophy at the last ophthalmic visit (Table 1).
Similar to other types of retinal degeneration, retinal vascular
attenuation and optic nerve pallordparticularly temporal pallor
involving the papillomacular bundledalso occur in cblC575
Figure 2. Macular changes in cobalamin C are early and progressive and may include a developmental component. A, Fundus photograph showing macular
coloboma in a 12-month-old (patient 2) homozygous for c.271dupA (p.R91KfsX14). Coloboma was documented at 6 months of age or earlier, but pho-
tographs were not available from that time point. BeG, Fundus photographs of sibling pairs homozygous for c.271dupA (p.R91KfsX14) showing degen-
eration and the effect of prenatal or early treatment, or both, on the course of macular degeneration. B, C, Fundus photographs from patient 5 obtained at
(B) 5 years of age and (C) 10 years of age (visual acuity [VA], 0.8 logarithm of the minimum angle of resolution [logMAR]), who was treated with
hydroxocobalamin injections starting at 5 days of age. D, Fundus photograph of patient 6, older sibling of patient 5, obtained at 9 years of age (VA, 1.6
logMAR). E, F, Fundus photographs of patient 4, diagnosed and treated prenatally, obtained at (E) 5 years of age (VA, 0.7 logMAR) and (F) 10 years of age
(best-corrected VA, 1.0 logMAR). G, Fundus photograph of patient 8, who was not treated prenatally and is the older sibling of patient 4, at 10 years of age
(VA, ﬁx and follow). The table below the ﬁgure reports the total plasma homocysteine (tHcy), serum methylmalonic acid (MMA), and plasma methionine
(Meth) concentrations (mM) for the patients at each time point. *Past history of higher MMA levels, with a high of 4.4mM at 8 years of age.
Ophthalmology Volume 123, Number 3, March 2016deﬁciency. In most cases, these ﬁndings track with the severity of
the retinal degeneration, but there are exceptions. For example, 4-
year-old patient 15 with genotype c.271dupA (p.R91KfsX14),
c.331C>T (p.R111X) exhibited no apparent macular degeneration,
but showed temporal pallor clinically (Table 1; Fig 3D). However,
patient 16 (10 years of age), who shares the same genotype, did not
exhibit optic pallor (Table 1).
None of the later-onset patients in our study (patients 22e25)
experienced clinical macular degeneration. Two of these patients
are pictured in the ﬁnal panels of Figure 2. Figure 3E shows patient
23 (7 years of age), who was formally diagnosed just before 5 years
of age because of behavioral and cognitive changes in school. This
patient had increased plasma tHcy and MMA concentrations but
showed no macular degeneration. Patient 24 (21 years of age)
with late-onset disease showed no functional defect in vision,
nystagmus, or strabismus; however, drusen-like deposits were
apparent on the fundus examination (Fig 3F). Note the lack of
autoﬂuorescence of the deposits in the photograph to the right.
True drusen would autoﬂuoresce and also would be atypical in
patients of this age.
Fundus autoﬂuorescence imaging, ERG, and OCT were used to
characterize further the degeneration in 2 c.271dupA
(p.R91KfsX14) homozygous patients. Figure 4A is a wide-ﬁeld
autoﬂuorescence photograph from patient 14, a 27-year-old with
end-stage degeneration who is also pictured in Figure 3A. Note the
signiﬁcant hyperautoﬂuorescence in the periphery and macula and
the hyperautoﬂuorescence in the center. These autoﬂuorescence
results show that retinal pigment epithelium pathologic features576coexist with photoreceptor degeneration. Also, despite
widespread macular atrophy, there is a clear zone of peripheral
sparing. In addition, there is peripapillary sparing around the
optic nerve. In the OCT image in Figure 4B, from near the edge
of the macular lesion, atrophy and loss of laminar structure
extend well beyond the lesion. Also note the abnormal
reﬂectivity, a pattern consistent with end-stage degeneration, and
possible indications of developmental abnormalities. The ERG
results obtained from this patient at 27 years of age are displayed in
Figure 4D. Both scotopic and photopic responses are reduced and
delayed (scotopic>photopic), but are remarkably preserved
considering the macular condition. Figure 4C shows OCT
images of a cut passing through the central macular lesion of
patient 11 (also shown in Fig 2B) and shows extreme thinning,
some preservation of retinal lamination, and nearly complete loss
of the outer nuclear layer.Discussion
Our study details the clinical course of 25 cblC deﬁciency
patients ranging in age from 2 to 27 years, with particular
focus on the ophthalmic manifestations of the disease over
time. Both patients with infantile-onset and later-onset dis-
ease were included. Our study includes the oldest
c.271dupA (p.R91KfsX14) homozygous patients in the
literature to date, with 5 patients 18 through 27 years of age
Figure 3. Retinal degeneration occurs in cobalamin C deﬁciency independent of metabolic status and within a variety of genotypes. Metabolite levels (in
mM) at the time of examination are listed to the right or left of each panel. A, Fundus photograph showing a macular coloboma in patient 14 at 30 years of
age (visual acuity [VA], 1.51 logarithms of the minimum angle of resolution [logMAR]; c.271DupA [p.R91KfsX14] homozygous). Despite the severe
degeneration, a small portion of the retina is preserved. B, Wide-ﬁeld photograph of patient 11 obtained at 17 years of age (VA, 1.51 logMAR; c.271DupA
[p.R91KfsX14] homozygous). Note bone spicules and signiﬁcant progression despite youth. C, Fundus photograph from patient 18 obtained at 22 years of
age, whose genotype is the relatively unusual c.271dupA (p.R91KfsX14), c.600G>A (p.W200X). Although the retina is relatively preserved, central
nervous system involvement severely affects vision (right-eye VA, 1.2 logMAR). D, Fundus photograph from patient 15 obtained at 14 years of age, with
moderate total plasma homocysteine (tHcy) and methylmalonic acid (MMA) concentrations, showing some optic nerve pallor but no clinical macular
degeneration (c.271dupA [p.R91KfsX14], c331C/T [p.R111X] genotype). E, Fundus photograph from patient 23 obtained at 7 years of age. This patient
with later-onset disease had abnormal tHcy and MMA concentrations and showed no macular degeneration. F, Fundus photograph from patient 24 obtained
at 21 years of age. This patient with later-onset disease had normal vision (0 logMAR) and no macular degeneration, but did show drusen-like deposits.
Panel inset, Autoﬂuorescence photograph of the same retinal area as in (F). Note the lack of autoﬂuorescence of the drusen-like deposits.
Brooks et al  Manifestations of Cobalamin C Deﬁciencyat the last ophthalmic visit (Table 1). Previously, the oldest 2
patients who are c.271dupA (p.R91KfsX14) homozygous
reported in the literature were 17 and 23 years of age
when the ophthalmic ﬁndings were made,14,18 although
there may be older patients in the literature without reported
genotypes. In the infantile-onset group, patients are severely
affected compared with late-onset patients, and neonatal and
infantile presentation of systemic symptoms (e.g., failure to
thrive, encephalopathy, acute lethargy) also is accompanied
by overt ophthalmic signs. These signs often occur before 1
year of age and include manifest nystagmus (16/21 [76%]),macular degeneration (7/21 [33%]), and irregular macula
and reduced ERG results (patient 9 at 3 months of age and
patient 11 at 1 month of age). An additional rare and severe
early manifestation, ﬁrst reported recently in a patient in the
ﬁrst year of life,23 is macular coloboma, as seen in patient 3
(3 months of age; Table 1). Although coloboma also is seen
in some, but not all, older patients with cblC deﬁciency as
they progress to end-stage macular degeneration (Table 1;
Fig 3A),18 coloboma seen in the ﬁrst few months of life
could represent either very severe degenerative processes,
abnormal ocular development at the time of birth, or both.577
Figure 4. Pathologic and functional analysis of c.271DupA (p.R91KfsX14) homozygotes showing preservation of peripheral retinal structure and function
and retinal architecture consistent with a developmental defect. A, Autoﬂuorescence photograph from patient (pt) 14 obtained at 27 years of age showing
end-stage degeneration. Note the signiﬁcant hyperautoﬂuorescence in the periphery and macula and the hyperautoﬂuorescence in the center. Despite
widespread macular atrophy, there is a clear zone of peripheral sparing. In addition, there is clear peripapillary sparing around the optic nerve. B, Cirrus high-
resolution optical coherence tomography (OCT) raster scan from near the edge of the macular atrophic lesion (inset) showing atrophy and loss of retinal
laminar structure extending well beyond the macular atrophic lesion. Note abnormal reﬂectivity and a pattern consistent with end-stage degeneration and
possible indications of developmental abnormalities. C, Cirrus high-resolution OCT raster scan from the center of the macular atrophic lesion (inset)
showing loss of the inner segmenteouter segment photoreceptor junction within the macular lesion. The scan shows relatively normal retinal architecture
beyond the macular lesion with an abrupt transition (white arrows depict the boundaries of the lesion on this scan). D, Electroretinography (ERG) results
obtained from patient 14 showing that both scotopic and photopic responses are reduced and delayed (scotopic>photopic), but remarkably preserved
considering the macular condition. E, Electroretinography results obtained from patient 11 at 17 years of age showing signiﬁcant attenuation and delay of
both scotopic and photopic responses (wide-ﬁeld photograph in Fig 2B). OD ¼ right eye; OS ¼ left eye.
Ophthalmology Volume 123, Number 3, March 2016A high prevalence of clinically signiﬁcant structural heart
defects have been found in cblC-deﬁcient patients,22,24 and
the patients in this study also showed a number of devel-
opmental defects (e.g., microcephaly, nonehead-sparing
intrauterine growth restriction, and cardiac noncompaction;
Table 1), perhaps consistent with the recent observations
suggesting Mmachc deﬁciency is critical for
preimplantation during early mouse development.25 A role
for this enzyme in human ocular development is suggested
by the recent documentation, via spectral-domain OCT, of
ocular changes from infancy to 13 years of age in one
c.271dupA (p.R91KfsX14) homozygous patient in whom
photoreceptor outer segment loss, thinning of the outer578nuclear layer, and a thickened, delaminated inner retina
resembling an immature retina were noted.23 Other
investigators have observed progressive degeneration via
OCT imaging performed at 4 and 7 months of age.18 The
fact that we and others also have observed similar changes
in retinal structure (Fig 4B, C),18,23 that patients can
demonstrate severe disease in infancy, and that comorbid
developmental abnormalities exist reinforces the concept
that cblC deﬁciency comprises a developmental as well as a
degenerative phenotype.
In our series, we did not observe a neuroanatomic-
retinopathy correlation beyond noting that some patients who
had early encephalopathy also had cortical vision problems
Brooks et al  Manifestations of Cobalamin C Deﬁciency(patients 6, 14, and 17). However, patients with unrevealing
imaging studies also had retinopathy or optic nerve disease
(patients 3, 9, 10, and 11). This agrees with the claims of Ricci
et al,26 who noted that brain lesions were not the only cause of
visual abnormalities in cblC-deﬁcient individuals.
Conversely, we ﬁnd that some patients with severe central
nervous system impairments also could have largely
unaffected retinal structures (patients 18 and 23).
Additionally, the ocular examination results of the 1 patient
in our cohort with hydrocephalus (patient 10) were very
similar to those of same-age nonhydrocephalus patients. We
think it is unlikely she experienced pressure effects, but it
cannot be completely ruled out. A detailed description of
neuroradiologic imaging studies in this cohort is in progress.
In cblC deﬁciency, as in many metabolic disorders, im-
provements in treatments can ameliorate systemic symptoms
and can improve patient life spans. Therefore, late ocular
manifestations with underlying similarities to other diseases
with disrupted bioenergetics now are being noted and afford
an opportunity to speculate about the pathophysiology un-
derlying the ocular disease manifestations. Guttae found on
the corneal endothelium of both eyes of a 27-year-old pa-
tient (patient 14) may be one example. These deposits in the
corneal endothelial basement membrane associated with
endothelial cell loss27e29 have not been previously reported
in cblC deﬁciency. Guttae (as well as retinal dystrophy and
optic neuropathy) do appear in other diseases linked to
mitochondrial dysfunction, such as Kearns-Sayer disease
and Leber hereditary optic neuropathy.30,31 Whether this is
the secondary manifestation of mitochondrial dysfunction,
well known to be a pathologic characteristic of methyl-
malonic acidemia,32 is unknown, but is supported by a case
study that described a patient with late-onset cblC deﬁciency
whose muscle biopsy showed mitochondrial respiratory
chain defect with cytochrome oxidase (complex IV) deﬁ-
ciency.33 Furthermore, a postmortem pathologic study of a
2-year-old cblC-deﬁcient patient with macular degenera-
tion16 documented swollen mitochondria and large vacuoles
in the corneal endothelium. This patient also showed an
accumulation of mucopolysaccharides in the sclera,
potentially because of lysosomal dysfunction, and
degenerated mitochondria in the iris pigment epithelium.16
Whether such an accumulation is a factor in the unusual
ﬁnding of drusen-like deposits on the macula of late-onset
patient 24 (Fig 3F)dwhich, like the guttae, has not been
seen previously in cblC-deﬁcient patientsdremains
unknown but is worthy of exploration in other older cblC-
deﬁcient patients. As others have described, we found that
most late-onset cblC-deﬁcient patients do not manifest
visible retinal pathologic features. One caveat is that we
have conducted limited longitudinal examinations in this
small subgroup of patients. Although we do not have repeat
visits within our late-onset patient cohort, we do have 2 late-
onset patients of the same genotype (patients 22 and 23)
who are separated in age by decades and yet have no
detectible eye disease. This is worth noting and perhaps an
area for future research. Furthermore, it is worth noting that
1 of the 4 late-onset patients reported by Gerth et al12
showed normal ERG results despite some clinically
apparent retinal pathologic features.We were limited in this study by not being able to
examine patients under anesthesia, and therefore we could
not assess electrophysiologic measurements or OCT data in
many patients. In addition, 12 patients were seen only once,
limiting our ability to provide longitudinal follow-up across
the cohort.
In our study, pace and chronicity of the ophthalmic
manifestations in early-onset cblC deﬁciency lacked strict
correlation to metabolic status as measured at the time of
visit, because poorly controlled patients could have
relatively intact retinas, and conversely, patients with
well-controlled disease experienced widespread atrophy.
Conversely, crystalline lens dislocation, as seen resulting
from cystathionine b-synthase deﬁciency homo-
cystinuria,34 was not observed in any of our patients
despite high levels of tHcy. This implies that the
mechanism of lens dislocation is not related to tHcy per
se. However, elevated tHcy may increase the amounts
of reactive oxygen species, leading to activation of
microglia35 and induction of apoptosis in neurons and
the vascular endothelium.36e38 Data obtained by
Richard et al39 from ﬁbroblast studies of isolated
homocystinuria patients (cblE, cblG, and MTHFR
deﬁcient) indicate that the impaired remethylation
capacity in patients may increase reactive oxygen
species and apoptosis levels. Similarly, patients with
isolated MMA (e.g., mut0, cblB) sustain much higher
levels of MMA (mmol/L range) and yet have no
macular or retinal degeneration (unpublished
observation).40
Of the inherited forms of MMA, the cblC retinal atrophy
seems to be unique, with 1 reported exception in a patient
with cobalamin D deﬁciency.41 Low methionine levels have
been hypothesized to be a pathophysiologic mechanism for
cblC deﬁciency ocular disease, either through causing
inadequate protein synthesis10 or a decrease in cysteine
synthesis, and therefore decreased levels of retinal
pigment epitheliumeprotecting glutathione.11,42 Because
other cobalamin deﬁciencies (e.g., cobalamin G) have low
methionine without eye disease, this mechanism is more
likely to be contributory rather than causative. There have
been encouraging reports describing the use of methionine
to improve retinal function, including rescued rod function
in a 3-year-old cblC-deﬁcient patient.43 The fact that other
forms of cobalamin-associated hyperhomocysteinemia,
such as cobalamin E and cobalamin G deﬁciencies, do not
display a retinopathy suggests that a more complex mech-
anism underlies the eye disease in cblC deﬁciency, espe-
cially because methylenetetrahydrofolate reductase
deﬁciency patients, who also have homocystinuria, do not
experience retinal degeneration. In total, the patient obser-
vations suggests that the pathogenesis of the retinal ﬁndings
in cblC deﬁciency is the result of a unique underlying
pathophysiologic mechanism or disrupted bioenergetics,44
rather than toxic metabolites45 per se. However, more data
on the ophthalmologic phenotype of patients with these
rarer defects is needed. Analyte levels during study visits
may or may not correlate with past history, especially
because the patient ages varied widely and the disease
progression was continuous. Based on the observations579
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metabolite levels, we speculate that although metabolic
control is desirable, it is probably not the most
deterministic factor in cblC-related ocular disease.
In contrast, genotypes were very predictive for ophthalmic
prognosis in cblC deﬁciency. c.271dupA (p.R91KfsX14)
homozygous patients were severely affected universally,
both in our study and in the literature.14,46,47 Compared with
our c.271dupA (p.R91KfsX14) homozygous patients, the
results for c.271dupA (p.R91KfsX14) homozygous patients
in the literature are very similar.14,23,48e51
Although c.271dupA (p.R91KfsX14) homozygous
patients also were the most severely affected over time,
certain mutations in transdc.271dupA (p.R91KfsX14),
c.457C>T p.R153X; c.440G>A (p.G147D), c.619dupG
(p.D207GfsX38); and c.471G>A (p.W157X), c.666C>A
(p.Y222X)dalso resulted in severe eye disease, whereas
others manifested a comparatively less severe ocular
phenotype. Lerner-Ellis et al8 showed through allelic
expression studies of human cblC ﬁbroblasts that in early-
onset mutations, c.271dupA (ex2/dup, frameshift) and
c.331C>T (ex3/nonsense) MMACHC mRNA transcripts
were underexpressed compared with control alleles and the
later-onset c.394C>T p.R132X mutation. According to cur-
rent understanding, nonsense mutations would be expected to
be subjected to nonsense-mediated decay and loss of protein.
However, there is some evidence that prematurely truncated
MMACHC proteins can retain some functionality.52 This
may be the reason behind the unusual phenotype of patient
18, who has a c.271dupA (p.R91KfsX14), c.600G>A
(p.W200X) genotype and whose retina is quite preserved
despite severe metabolic disease.
Diagnostic and surveillance guidelines for ocular disease
in patients with cblC defect have been proposed recently,
and more data on early and late manifestations also could
improve our understanding of the disease and processes.18
One outstanding question in particular is perplexing:
because biochemical measures ameliorate systemic
symptoms of cblC disease, why is the associated macular
degeneration resistant to treatment? Prenatal or early
treatment, or both, with hydroxocobalamin may ameliorate
the developmental and behavioral complications of cblC
deﬁciency somewhat, both in our experience (data not
shown) and in the literature.15,53,54 We also observed that
prenatal or early treatment, or both, may partially mitigate
the ocular disease. Our younger affected siblings had better
functional acuity in the early years and as they approached
their second decade (Table 1; Fig 2), but still progressed to
severe macular atrophy.
Perhaps the water-soluble nature of vitamin B12 is an
obstacle to penetration into the ocular compartment, and the
use of repeated subconjunctival injection,55 small-volume
nebulizer,56 and more recently, periocular injection of in situ
hydrogels57 or subconjunctival biodegradable microﬁlms58
may be a more efﬁcient means to deliver the cofactor in
these patients. Clearly, research on potential therapeutics
would be enhanced signiﬁcantly if a viable animal model of
cblC deﬁciency could be generated and studied.580References
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